已发表论文

PD-1 阻断可恢复体外扩增 CD8+ T 细胞受损的功能,促进错配修复缺陷 EpCAM+PD-L1+ 癌细胞的凋亡

 

Authors Kumar R, Yu F, Zhen YH, Li B, Wang J, Yang Y, Ge HX, Hu P, Xiu J

Received 13 December 2016

Accepted for publication 27 May 2017

Published 13 July 2017 Volume 2017:10 Pages 3453—3465

DOI https://doi.org/10.2147/OTT.S130131

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ashok Kumar Pandurangan

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati

Background: Adoptive T cell therapy has been proven to be a promising modality for the treatment of cancer patients in recent years. However, the increased expression of inhibitory receptors could negatively regulate the function and persistence of transferred T cells which mediates T cell anergy, exhaustion, and tumor regression. In this study, we investigated increased cytotoxic activity after the blockade of PD-1 for effective immunotherapy.
Methods: The cytotoxic function of expanded CD8
+ CTLs and interactions with tumor cells investigated after blocking of PD-1. Ex vivo expanded CD8+ CTLs were co-cultured with mismatch repair (MMR) stable or deficient (high microsatellite instability [MSI-H]) EpCAM+ tumor cells. The levels of IFN-γ and GrB were detected by enzyme-linked immunosorbent spot assay. Flow cytometry and confocal microscopy were used to assess CD107a mobilization, cytosolic uptake, and cell migration. 
Results: A dramatic increase in PD-1 expression on the surface of CD8
+ CTLs during ex vivo expansion was observed. PD-1 level was downregulated by approximately 40% after incubation of the CD8+ CTLs with monoclonal antibody which enhanced the secretion of IFN-γ, GrB, and CD107a. Additionally, PD-1 blockade enhanced cell migration and cytosolic exchange between CD8+ CTLs and MMR deficient (MSI-H) EpCAM+PD-L1+ tumor cells.
Conclusion: The blockade of PD-1 enhanced the cytotoxic efficacy of CD8
+ CTLs toward MMR deficient tumor cells. In conclusion, we propose that blocking of PD-1 during the expansion of CD8+ CTLs may improve the clinical efficacy of cell-based adoptive immunotherapy.
Keywords: PD-1, CTLs, MSI-H, EpCAM
+PD-L1+, cancer immunotherapy